Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.
Shanghai Fosun Pharmaceutical said that its subsidiary Yaopharma Co. has received approval from China’s National Medical Products Administration to market Flurbiprofen Axetil Injection. The drug is a chemical injection product indicated for post-surgical and cancer-related pain relief, potentially strengthening the group’s analgesic portfolio and reinforcing its positioning in hospital-based pain management therapies.
The approval of Flurbiprofen Axetil Injection adds to Fosun Pharma’s branded generics pipeline and may support revenue growth in China’s competitive anesthetic and analgesic market. By expanding its range of pain management solutions under the marketing authorization of Yaopharma, the group continues to deepen its footprint in high-demand therapeutic areas aligned with rising surgical and oncology treatment volumes.
The most recent analyst rating on (HK:2196) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a diversified Chinese healthcare company engaged in the research, development, manufacturing and distribution of pharmaceutical products. Through subsidiaries such as Yaopharma Co., it focuses on prescription drugs and other medical therapies for both domestic and international markets, with a strong presence in hospital and specialty care segments.
Average Trading Volume: 2,881,866
Technical Sentiment Signal: Hold
Current Market Cap: HK$75.44B
Learn more about 2196 stock on TipRanks’ Stock Analysis page.